Insider Cluster (4 insiders) ·Filed May 4, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago
Insider cluster: 4 insiders, $0.3M total
Actionable Insight • Neutral

The cluster is too small to drive a trading signal. Monitor for any upcoming earnings or pipeline catalysts that could explain the timing, but the dollar amounts suggest routine diversification. No action warranted.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
ARQT ▲ +18.60% at T+60d
NEUTRAL call ✓ call won +18.60% · α vs SPY +16.75% · entry $23.49 → $27.86
Entry anchored
May 1, 03:59 PM ET
via exchange tick
T+1d
-0.30%
call -0.30% · α -1.09%
$23.42
settled 5mo ago
T+5d
-9.58%
call -9.58% · α -12.51%
$21.24
settled 5mo ago
T+20d
-8.60%
call -8.60% · α -14.24%
$21.47
settled 4mo ago
T+60d
+18.60%
call +18.60% · α +16.75%
$27.86
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Four Arcutis insiders sold a total of $283K in open-market sales over a one-week window, including the CFO and three other executives. The cluster is modest in size (0.01% of market cap) and occurred near the stock's recent highs, suggesting routine portfolio diversification rather than a coordinated bearish signal. The cross-filing actuarial verdicts amplify the cluster's significance, but the absolute dollar value is too small to warrant a directional call.

Key Financial Metrics

Direction
selling
Total Value
$283.0K
Insiders
4

Key Facts

  • Four insiders sold a total of $283K in open-market sales from May 4-11, 2026
  • CFO Latha Vairavan sold $32K; Matsuda Masaru sold $172K (largest trade)
  • Total sales represent ~0.01% of ARQT's $2.6B market cap — well below the 0.1% materiality threshold
  • All sales were open-market (code S); no non-cash transactions in the cluster
  • Stock traded between $21.05 and $23.61 during the window, near recent highs

Financial Impact

$283K in insider sales, negligible relative to $2.6B market cap

insider ownership

Risk Factors

  • Insider sales could accelerate if the stock continues to rally
  • No material business catalyst identified — cluster may be purely liquidity-driven

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ARQT-1778715778269
17 reports for ARQT
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +14.74%Mar 2, 2026
Filters
Rows
Reports for ARQT — sortable, filterable
TypeNow
Aug 24, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.86 $26.38▲ +6.11%▲ +5.87%$25.16 (+1.21%)
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.08 $25.96▲ +3.51%▲ +4.04%$25.16 (+0.32%)
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.35 $25.38▲ +0.12%▲ +0.12%$25.16 (−0.75%)
Aug 11, 2026
7w ago
144
NEUTRAL ★ 3/10
$26.28 $23.38▼ −11.04%▼ −9.14%$25.16 (−4.26%)
Aug 6, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.43 $23.66▼ −10.48%▼ −11.08%$25.16 (−4.81%)
Aug 5, 2026
8w ago
Press Release
BULLISH ★ 7/10
$26.43 $23.66▼ −10.48%▼ −11.08%$25.16 (−4.81%)
Aug 3, 2026
8w ago
144
NEUTRAL ★ 2/10
$26.03 $23.75▼ −8.76%▼ −7.52%$25.16 (−3.34%)
Jun 29, 2026
13w ago
Press Release
BULLISH ★ 7/10
$26.22 $27.84▲ +6.18%▲ +7.21%$25.16 (−4.04%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.21 $27.74▲ +5.84%▲ +5.30%$25.16 (−4.01%)
Jun 9, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$23.23 $28.78▲ +23.89%▲ +20.27%$25.16 (+8.31%)
Showing 10 of 17

US Market Status

Market Closed — Opens Mon (64h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 13, 2026